We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Eli Lilly has partnered with UK-based MiNA Therapeutics to develop treatments using small activating RNA (saRNA) technology, a new class of drugs pioneered by MiNA. Read More
Amplyx’s Fosmanogepix is being evaluated in ongoing phase 2 trials in both intravenous and oral formulations for treatment of life-threatening fungal infections. Read More
Deliveries of the J&J vaccine, which were recently paused as the European Medicines Agency investigated the risk of blood clots, are now resuming in Europe with a blood clot warning added to the product information. Read More
AstraZeneca (AZ) reportedly may not file for FDA Emergency Use Authorization (EUA) of its COVID-19 vaccine until mid-May as it needs more time to gather supporting data. Read More
Moderna said it plans to produce up to 3 billion doses of its messenger RNA-based COVID-19 vaccine globally in 2022, including booster shots against viral variants and pediatric vaccines. Read More
Pfizer has acquired San Diego, Calif.-based Amplyx Pharmaceuticals, broadening its portfolio of potential therapies for treating drug-resistant fungal infections. Read More